New hope for inoperable brain tumors: radioactive drug trial launches

NCT ID NCT04082520

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a radioactive drug called Lutathera for people with a type of brain tumor (meningioma) that cannot be removed by surgery and has continued to grow after radiation therapy. The drug is given through a vein and targets tumor cells to stop them from growing. The trial aims to see if it is safe and effective for these hard-to-treat tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRADE 1 MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign meningioma grade II meningioma grade III meningioma meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRADE 1 MENINGIOMA GRADE 2 MENINGIOMA GRADE 3 MENINGIOMA RECURRENT MENINGIOMA UNRESECTABLE MENINGIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.